August 28, 2026
HPV Vaccine | Mpox | Polio | Ebola | COVID: Active Vaccination/Immunity
Progress Toward Poliomyelitis Eradication ― Afghanistan | Moderna Received FDA Emergency Use Authorization For Their Omicron-Targeting Bivalent Covid-19 Booster Vaccine In Children | Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons | Authorized Updated (Bivalent) COVID-19 Vaccines for Children | Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster | Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir | The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post–COVID-19 conditions | Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters
SARS-CoV-2 Serology and Self-Reported Infection Among Adults — National Health and Nutrition Examination Survey, United States, August 2021–May 2022 | Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes | Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals
| Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants | Mpox (formerly monkeypox) in women: epidemiological features and clinical characteristics of mpox cases in Spain, April to November 2022 | Triage of patients with Ebola virus disease
Is the risk of still and preterm birth affected by the timing of symptomatic SARS-CoV-2 infection during pregnancy? | Effectiveness of Influenza Vaccination of Pregnant Women for Prevention of Maternal and Early Infant Influenza-Associated Hospitalizations in South Africa | A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes | Single and 2-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic® induce durable B cell memory responses comparable to replicating smallpox vaccines | Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected and infection-naive individuals
Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 | Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection | Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution | Can SARS-CoV-2 trigger new onset of autoimmune disease in adults? A case-based review | Protection against Omicron from Vaccination and Previous Infection in a Prison System | Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19
Severe Monkeypox in Hospitalized Patients — United States, August 10–October 10, 2022 | Reinfections with Different SARS-CoV-2 Omicron Subvariants, France (CDC) | In adults with COVID-19, melatonin was assessed for effects on inflammatory markers, clinical signs and symptoms, and mortality | Influenza Incidence and Vaccine Effectiveness During the Southern Hemisphere Influenza Season — Chile, 2022 | Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants | Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Progress Toward Poliomyelitis Eradication — Pakistan, January 2021–July 2022 | Polio by the Numbers—A Global Perspective | Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV Seropositive Children 12–24 Months | Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox — United States, May 22–October 10, 2022 | Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages
A healthcare-associated infection with Monkeypox virus of a healthcare worker during the 2022 outbreak | Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomized ascending dose phase I trial | Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment | Early outpatient treatment with remdesivir in patients at high risk for severe COVID-19: a prospective cohort study
Possible Occupational Infection of Healthcare Workers with Monkeypox Virus, Brazil | Protection of SARS-CoV-2 natural infection against reinfection with the BA.4 or BA.5 Omicron subvariants | Rates of Monkeypox Cases by Vaccination Status | Paxlovid Significantly Reduces COVID-19 Hospitalizations and Deaths | Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
Increase in Acute Respiratory Illnesses Among Children and Adolescents Associated with Rhinoviruses and Enteroviruses, Including Enterovirus D68 — United States, July–September 2022 | Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 | Long Covid—An Update for Primary Care | A distinct symptom pattern emerges for COVID-19 long-haul: A Nationwide Study | SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain | Breakthrough Infection by SARS-CoV-2 Delta and Omicron Variants Elicited Immune Response Comparable to mRNA Booster Vaccination
September 29, 2022 Read More »
Un recurso educativo integral sobre todos los aspectos de las enfermedades parasitarias y su impacto en la humanidad en todo el mundo.
Ayude a llevar la información médica y biológica más reciente sobre enfermedades causadas por parásitos eucariotas a todos los médicos y estudiantes de medicina en los Estados Unidos.